BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 16, 2009-- Bruker Corporation (NASDAQ: BRKR) today announced that it has appointed Dr. Bernd Gewiese and Dr. Werner Maas as Co-Presidents of its Bruker BioSpin division, with an effective date of February 1st, 2010. Presently, both are serving as Executive Vice Presidents of Bruker BioSpin.
Frank Laukien, Bruker’s President and CEO, commented: “As Bruker approaches its 50th anniversary, its Bruker BioSpin division today is the global technology and market leader in NMR, EPR and pre-clinical MRI. The appointment of Drs. Bernd Gewiese and Werner Maas as division Co-Presidents signifies a continuation of Bruker BioSpin’s unmatched commitment to ‘innovation for customers, delivered with integrity’. With a strong focus on operational excellence and continued investment in exciting new technologies and growth opportunities, Bruker is looking forward to a bright future of its magnetic resonance business.”
Biographies
Dr. Bernd Gewiese received his Ph.D. for in vivo NMR/MRI from the Technical University of Berlin, Germany. He joined Bruker in 1992 as MRI product manager, after five years of scientific work in MRI at the Steglitz Klinikum of the Free University of Berlin. In 1999, he was appointed as managing director of Bruker BioSpin MRI GmbH, and in 2005 he was appointed as Executive Vice President of Bruker BioSpin MRI. In 2007, Dr. Gewiese took over the management of Bruker BioSpin GmbH in Germany, and also was appointed as Executive Vice President of the Bruker BioSpin division.
Dr. Werner Maas obtained a Ph.D. in solid-state NMR from the University of Nijmegen in The Netherlands. He joined Bruker in 1992 as a Postdoctoral Fellow in the US, and stayed on as a Research Scientist. In 2001, he was appointed as Vice President for R&D, and in 2005 he also became Vice President for MRI in the US. In 2007, Dr. Maas was appointed as Executive Vice President of the Bruker BioSpin division.
ABOUT BRUKER CORPORATION
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation, please visit www.bruker.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties, that could cause actual future results to differ materially from those projected including, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
Source: Bruker Corporation
Bruker Corporation
Stacey Desrochers, +1-978-663-3660, ext. 1115
Director of Investor Relations
stacey.desrochers@bruker.com